HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hidenori Arai Selected Research

(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acid

9/2021Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
1/2021Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
11/2019Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
2/2019Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
1/2019Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
11/2018Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
9/2018Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
6/2018Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
1/2018Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
1/2018Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hidenori Arai Research Topics

Disease

15Diabetic Nephropathies (Diabetic Nephropathy)
08/2015 - 04/2004
13Sarcopenia
10/2022 - 02/2014
13Dyslipidemias (Dyslipidemia)
06/2022 - 01/2012
13Frailty
03/2022 - 11/2013
12Atherosclerosis
09/2018 - 09/2004
10Coronary Artery Disease (Coronary Atherosclerosis)
08/2022 - 10/2010
10Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
08/2022 - 12/2008
8Inflammation (Inflammations)
10/2022 - 06/2005
8Cardiovascular Diseases (Cardiovascular Disease)
08/2022 - 06/2009
8Xanthomatosis (Xanthoma)
06/2022 - 01/2012
7Dementia (Dementias)
12/2021 - 01/2012
7Hypertriglyceridemia
01/2021 - 06/2008
7Insulin Resistance
11/2018 - 12/2008
7Glomerulonephritis
01/2016 - 02/2005
6Drug-Related Side Effects and Adverse Reactions
08/2021 - 05/2004
6Albuminuria
10/2016 - 05/2003
6Body Weight (Weight, Body)
01/2015 - 12/2008
5Hypertension (High Blood Pressure)
05/2022 - 01/2013
5Acute Coronary Syndrome
12/2021 - 10/2010
5Stroke (Strokes)
12/2021 - 10/2012
5Type 2 Diabetes Mellitus (MODY)
01/2019 - 12/2008
5Obesity
01/2016 - 06/2008
5Hypertrophy
01/2012 - 05/2003
5Metabolic Syndrome (Dysmetabolic Syndrome X)
03/2010 - 01/2005
4Inborn Genetic Diseases (Disease, Hereditary)
05/2022 - 12/2008
4Neoplasms (Cancer)
01/2022 - 05/2010
4Diabetes Mellitus
10/2021 - 05/2004
4Coronary Disease (Coronary Heart Disease)
02/2021 - 01/2016
3COVID-19
01/2022 - 12/2020
3Peripheral Nervous System Diseases (PNS Diseases)
10/2021 - 01/2018
3Malnutrition (Nutritional Deficiencies)
08/2021 - 02/2014
3Hyperglycemia
01/2011 - 04/2004
2Muscle Weakness
01/2022 - 01/2017
2Rheumatoid Arthritis
10/2021 - 06/2019
2Chronic Obstructive Pulmonary Disease (COPD)
03/2021 - 01/2021
2Pulmonary Arterial Hypertension
06/2019 - 06/2019
2Hypercholesterolemia
05/2019 - 11/2007
2Deglutition Disorders (Dysphagia)
02/2019 - 10/2012
2Hyperlipidemias (Hyperlipidemia)
09/2018 - 01/2016
2Heart Diseases (Heart Disease)
05/2018 - 01/2016
2Breast Neoplasms (Breast Cancer)
01/2018 - 01/2016
2Weight Loss (Weight Reduction)
08/2017 - 07/2017
2Death (Near-Death Experience)
06/2017 - 01/2016
2Heart Failure
05/2017 - 01/2017
2Ischemic Stroke
01/2016 - 01/2015
2Asthma (Bronchial Asthma)
01/2013 - 06/2005
2Chronic Renal Insufficiency
01/2012 - 11/2011

Drug/Important Bio-Agent (IBA)

24LipidsIBA
08/2022 - 03/2010
17oxidized low density lipoproteinIBA
06/2022 - 07/2007
14LDL CholesterolIBA
06/2022 - 08/2006
10(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
09/2021 - 01/2018
10Triglycerides (Triacylglycerol)IBA
01/2021 - 09/2004
10Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2019 - 11/2011
8Proteins (Proteins, Gene)FDA Link
10/2022 - 05/2004
8Pharmaceutical PreparationsIBA
05/2022 - 12/2008
8Glucose (Dextrose)FDA LinkGeneric
01/2021 - 08/2006
7LDL Lipoproteins (beta Lipoproteins)IBA
06/2022 - 07/2007
6HDL CholesterolIBA
05/2022 - 08/2006
6Insulin (Novolin)FDA Link
01/2021 - 05/2004
6CholesterolIBA
09/2018 - 09/2004
4Probucol (Lorelco)FDA Link
06/2022 - 12/2008
4Biomarkers (Surrogate Marker)IBA
03/2022 - 11/2008
4AlbuminsIBA
05/2018 - 11/2011
4CollagenIBA
10/2016 - 05/2004
4Streptozocin (Streptozotocin)FDA Link
05/2008 - 05/2003
3Lipoproteins (Lipoprotein)IBA
08/2022 - 09/2021
3Vitamin DFDA LinkGeneric
10/2021 - 08/2015
3HDL LipoproteinsIBA
02/2021 - 01/2012
3Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2021 - 01/2018
3Ezetimibe (Zetia)FDA Link
01/2019 - 01/2012
3Fenofibrate (CiL)FDA LinkGeneric
06/2018 - 01/2016
3Cholesterol Ester Transfer ProteinsIBA
01/2017 - 12/2008
3Advanced Glycation End ProductsIBA
01/2011 - 04/2004
3Messenger RNA (mRNA)IBA
03/2010 - 08/2004
3propagermanium (Ge 132)IBA
03/2010 - 09/2007
3Apolipoproteins E (ApoE)IBA
06/2009 - 09/2004
3Warfarin (Coumadin)FDA LinkGeneric
01/2008 - 05/2003
2ApolipoproteinsIBA
08/2022 - 07/2007
2omega-Chloroacetophenone (Mace)IBA
12/2021 - 01/2017
2hydroxide ionIBA
10/2021 - 08/2015
2AntioxidantsIBA
02/2021 - 12/2008
2Biological ProductsIBA
07/2019 - 07/2007
2anacetrapibIBA
01/2017 - 01/2016
2Blood Glucose (Blood Sugar)IBA
10/2016 - 08/2005
2Indicators and Reagents (Reagents)IBA
01/2016 - 01/2015
2Collagen Type IV (Type IV Collagen)IBA
01/2016 - 02/2005
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2015 - 01/2008
2ChemokinesIBA
01/2015 - 08/2012
2AllergensIBA
01/2013 - 06/2005
2pitavastatin (itavastatin)FDA Link
11/2011 - 10/2010
2Monoclonal AntibodiesIBA
03/2011 - 02/2005

Therapy/Procedure

16Therapeutics
02/2021 - 09/2007
7Long-Term Care
10/2021 - 07/2013
5Activities of Daily Living (ADL)
12/2021 - 08/2017
5Polypharmacy
08/2021 - 05/2004
5Drug Therapy (Chemotherapy)
08/2021 - 01/2016
4Palliative Care (Palliative Therapy)
09/2021 - 06/2017
3Secondary Prevention
02/2021 - 06/2016
2Terminal Care (Care, Terminal)
09/2021 - 01/2016
2Resistance Training
02/2019 - 07/2017